{
    "nct_id": "NCT05067283",
    "official_title": "A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",
    "inclusion_criteria": "For all participants:\n\n* Has measurable disease by RECIST 1.1 criteria\n* Has adequate organ function\n* Male participants must be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception unless confirmed to be azoospermic\n* Female participants must not be pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child-bearing potential (WOCBP); is a WOCBP and uses a contraceptive method that is highly effective, with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle and must have a negative highly sensitive pregnancy test within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention\n\nFor Arm 1 - Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease\n\nFor Arm 2\n\n- Has an untreated metastatic non-small cell lung cancer (NSCLC) with histologically OR blood-based confirmation of KRAS G12C mutation and histologic confirmation of programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%\n\nFor Arm 3\n\n* Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically or blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease Expansion Group A: 2L+NSCLC\n* Has histologically or cytologically confirmed diagnosis of unresectable or metastatic NSCLC with histological or blood-based confirmation of KRAS G12C mutation\n* Previous treatment failure of at least 1 line of systemic therapy Expansion Group B\n* Has locally advanced unresectable or metastatic solid-tumor malignancy, excluding NSCLC or CRC, with histologically or blood- based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease\n\nArm 4 only - Has an untreated advanced or metastatic nonsquamous NSCLC with histologically or blood-based confirmation of KRAS G12C mutation\n\nArm 5 only\n\n* Histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic colorectal adenocarcinoma and with histologically or blood-based confirmation of KRAS G12C mutation\n* Previous treatment failure of one or 2 previous line(s) of systemic therapy\n\nArm 6 only\n\n- Locally advanced unresectable or metastatic colorectal adenocarcinoma with histologically or blood-based confirmation of KRAS G12C mutation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before first dose of study intervention\n* Has a history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years\n* Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has an active infection requiring systemic therapy\n* Known history of HIV infection or. has a known history of Hepatitis B virus or known active Hepatitis C virus infection\n* Has a history of interstitial lung disease, noninfectious pneumonitis requiring active steroid therapy, or ongoing pneumonitis\n* Has an active autoimmune disease requiring systemic therapy\n* Has not fully recovered from any effects of major surgical procedure without significant detectable infection\n* Has one or more of the following ophthalmological findings/conditions: intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma; diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and/or a diagnosis of retinal degenerative disease\n* Has received live or live-attenuated vaccine within 4 weeks of study start\n\nArm 4 Only\n\n* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatories (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents [for example, piroxicam]) before, during, and for at least 2 days after administration of pemetrexed.\n* Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone",
    "miscellaneous_criteria": ""
}